康辰药业：控股股东刘建华拟减持不超3%公司股份

Core Viewpoint - Kangchen Pharmaceutical announced a share reduction plan by its controlling shareholder Liu Jianhua due to personal funding needs, which may impact the company's stock performance [1] Summary by Relevant Sections - Share Reduction Plan - Liu Jianhua plans to reduce his holdings by up to 4.7807 million shares, representing no more than 3% of the company's total share capital [1] - The reduction will occur within three months starting from 15 trading days after the announcement [1] - Method of Reduction - The share reduction will be executed through both centralized bidding and block trading methods [1] - Up to 1.5936 million shares will be sold via centralized bidding, while up to 3.1871 million shares will be sold through block trading [1] - Pricing and Uncertainty - The selling price will be determined based on the market price at the time of the reduction [1] - The implementation of this reduction plan carries uncertainty [1]